Inscripta Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
72
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
23
Inscripta General Information
Description
Developer of a gene-editing technology intended to offer scalable digital genome engineering with push-button simplicity. The company's technology generates low-cost libraries of thousands of designer protein, pathway or genome variants each with specifically defined and trackable mutations, enabling researchers to design, engineer, evaluate and track results.
Contact Information
Website
www.inscripta.comCorporate Office
- 5720 Stoneridge Drive
- Suite 300
- Pleasanton, CA 94588
- United States
Corporate Office
- 5720 Stoneridge Drive
- Suite 300
- Pleasanton, CA 94588
- United States
Inscripta Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 8. Later Stage VC | 31-May-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series E) | 05-Apr-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 30-Nov-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 11-Nov-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C1) | 29-Mar-2019 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 28-Feb-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 16-Feb-2017 | $23M | $29M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 10-May-2016 | $6.04M | $6.04M | Completed | Startup |
Inscripta Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C1 | ||||||||
| Series C | ||||||||
| Series B | 19,784,629 | $0.000010 | 6% | $1.17 | $1.17 | 1x | $1.17 | 13.44% |
| Series A | 5,157,970 | $0.000010 | 6% | $1.17 | $1.17 | 1x | $1.17 | 3.5% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Inscripta Comparisons
Industry
Financing
Details
Inscripta Competitors (10)
One of Inscripta’s 10 competitors is Illumina, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Illumina | Formerly VC-backed | San Diego, CA | ||||
| Mammoth Biosciences | Venture Capital-Backed | Brisbane, CA | ||||
| Horizon Discovery | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Deep Genomics | Venture Capital-Backed | Toronto, Canada | ||||
| EdiGene | Venture Capital-Backed | Beijing, China |
Inscripta Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Inscripta Patents
Inscripta Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240076697-A1 | Methods for increased nucleic acid-guided cell editing | Pending | 01-Sep-2022 | ||
| US-20240101614-A1 | Chaperones for heterologous expression systems | Pending | 25-Aug-2022 | ||
| US-20240052370-A1 | Modulating cellular repair mechanisms for genomic editing | Pending | 27-Jul-2022 | ||
| US-20230340448-A1 | Engineered enzymes and bioproduction of bakuchiol | Active | 04-Mar-2022 | ||
| EP-4486905-A1 | Engineered enzymes and bioproduction of bakuchiol | Pending | 04-Mar-2022 | C12N9/90 |
Inscripta Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Inscripta Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Counterpoint Global | Asset Manager | Minority | ||
| D1 Capital Partners | Hedge Fund | Minority | ||
| Durable Capital Partners | Hedge Fund | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| GoldenArc | Venture Capital | Minority |
Inscripta Acquisitions (3)
Inscripta’s most recent deal was a Merger/Acquisition with Sestina Bio. The deal was made on 18-Jan-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sestina Bio | 18-Jan-2023 | Merger/Acquisition | Biotechnology | ||
| Infinome Biosciences | 12-Dec-2022 | Merger/Acquisition | Biotechnology | ||
| Solana Biosciences | 05-Sep-2018 | Merger/Acquisition | Biotechnology |
Inscripta FAQs
-
When was Inscripta founded?
Inscripta was founded in 2015.
-
Where is Inscripta headquartered?
Inscripta is headquartered in Pleasanton, CA.
-
What is the size of Inscripta?
Inscripta has 72 total employees.
-
What industry is Inscripta in?
Inscripta’s primary industry is Biotechnology.
-
Is Inscripta a private or public company?
Inscripta is a Private company.
-
What is Inscripta’s current revenue?
The current revenue for Inscripta is .
-
How much funding has Inscripta raised over time?
Inscripta has raised $461M.
-
Who are Inscripta’s investors?
Counterpoint Global, D1 Capital Partners, Durable Capital Partners, Fidelity Management & Research Company, and GoldenArc are 5 of 23 investors who have invested in Inscripta.
-
Who are Inscripta’s competitors?
Illumina, Mammoth Biosciences, Horizon Discovery, Deep Genomics, and EdiGene are some of the 10 competitors of Inscripta.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
